According to a recent analysis by Tomohiko Yoshida and colleagues, the latest formulation of Adalimumab significantly reduces the RA burden, enhances the treatment's adherence quality, less pain during needle insertion and improves the treatment outcomes. Adalimumab is a TNF-alpha blocker delivered via subcutaneous injection. However, the drug is associated with the risk of serious infections and pain at the injection site. This study involved the optimization of a change in the existing Adalimumab on pain, outcomes and treatment outcomes.

All outcomes displayed a considerable difference (p < 0.001). Paired t-tests were applied as well. Injection pain with influenza vaccine and the present formulation were reported by 68% and 80% of the patients, respectively. Although, the ratio of the patients who felt pain with the new Adalimumab reduced to 20%.